Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients (Cisplatin)
Phase II Open-Label, Non-Randomized Trial of Cisplatin Chemotherapy in Patients With BRCA1-Positive Metastatic Breast Cancer
Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology
A PHASE2 clinical study on BRCA1 Mutation and Metastatic Breast Cancer, this trial is completed. The trial is conducted by Maria Sklodowska-Curie National Research Institute of Oncology and has accumulated 7 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — May 2018 [monthly]
Completed PHASE2
First recorded
Jul 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Maria Sklodowska-Curie National Research Institute of Oncology
- Pomeranian Medical University Szczecin
For direct contact, visit the study record on ClinicalTrials.gov .